| Bioactivity | Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease[1]. |
| Invitro | BMS-931699 通过生物大分子相互作用分析系统显示出对 T 细胞增殖的 Kd 为 0.41 nM[1]。BMS-931699 通过混合淋巴细胞反应 (MLR) 诱导的 T 细胞增殖的 EC50 为 2.9 nM 以及对全血中 CD28 受体占用 (RO) 的 EC50 为 4.4 nM[1]。 |
| Name | Lulizumab pegol |
| CAS | 1421830-13-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yang Z, et al. Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699. J Pharmacol Exp Ther. 2015 Dec;355(3):506-15. |